Healthcare [ 13/13 ] | Medical Devices [ 113/164 ]
NASDAQ | Common Stock
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally.
The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables.
The company also provides onsite technical training services.
Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications.
In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software.
Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007.
The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 24 | 0.00 Increased by +100.00% | -0.29 Increased by +100.00% |
| Mar 1, 24 | -0.26 Increased by +33.33% | -0.30 Increased by +13.33% |
| Jan 10, 24 | -0.26 Increased by +31.58% | -0.30 Increased by +13.33% |
| Aug 4, 23 | -0.33 Decreased by -6.45% | -0.35 Increased by +5.71% |
| May 5, 23 | -0.32 Increased by +8.57% | -0.36 Increased by +11.11% |
| Mar 3, 23 | -0.39 Decreased by -11.43% | -0.36 Decreased by -8.33% |
| Nov 10, 22 | -0.38 Increased by +39.68% | -0.37 Decreased by -2.70% |
| Aug 12, 22 | -0.31 Increased by +98.45% | -0.32 Increased by +3.13% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jan 31, 24 | 6.34 M Increased by +44.88% | -11.17 M Increased by +32.07% | Decreased by -176.30% Increased by +53.11% |
| Oct 31, 23 | 6.14 M Increased by +29.67% | -13.39 M Increased by +18.04% | Decreased by -217.93% Increased by +36.79% |
| Jul 31, 23 | 5.00 M Increased by +29.59% | -14.02 M Decreased by -7.07% | Decreased by -280.21% Increased by +17.37% |
| Apr 30, 23 | 5.04 M Increased by +21.03% | -13.89 M Increased by +6.99% | Decreased by -275.81% Increased by +23.15% |
| Jan 31, 23 | 4.37 M Decreased by -16.01% | -16.45 M Decreased by -12.61% | Decreased by -376.02% Decreased by -34.08% |
| Oct 31, 22 | 4.74 M Decreased by -31.31% | -16.34 M Increased by +34.61% | Decreased by -344.78% Increased by +4.81% |
| Jul 31, 22 | 3.86 M Decreased by -37.03% | -13.09 M Decreased by -10.64% | Decreased by -339.12% Decreased by -75.71% |
| Apr 30, 22 | 4.16 M Decreased by -32.14% | -14.93 M Decreased by -26.19% | Decreased by -358.89% Decreased by -85.95% |